It has been demonstrated that PDGFRA amplification is correlated with IDH1 mutation and associated with poorer prognosis in IDH1-mutant astrocytomas, CNS WHO grade 4, as compared to those without PDGFRA amplification [32]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).